MedTrace Logo

Evolution of Lymphocyte Populations Under Biotherapy in Inflammatory Bowel Disease

NCT02693340 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2016-06-24

No results posted yet for this study

Summary

This is a monocentric prospective study for the collection of biological samples (blood and biopsies) to be used for in vitro biomarker assay(s) performed to identify predictive markers of response to biological treatments in inflammatory bowel disease (IBD).

Conditions

Interventions

BIOLOGICAL

sampling

• Sampling period(s): * Blood: W0, W6, W14, W30 and W52 and relapse. * Biopsies and fecal: W0, W14 and M52 and relapse.

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Matthieu Allez, MD PhD · APHP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-03-31
Completion
2020-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02693340 on ClinicalTrials.gov